← Back to Clinical Trials
Recruiting NCT06536231

NCT06536231 Hemodynamic Variations During Remote Ischemic Conditioning in Critical Ill Patients

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06536231
Status Recruiting
Phase
Sponsor Lithuanian University of Health Sciences
Condition Critical Illness
Study Type INTERVENTIONAL
Enrollment 50 participants
Start Date 2024-01-01
Primary Completion 2024-12-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 85 Years
Study Type INTERVENTIONAL
Interventions
Remote ischemic conditioning

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 50 participants in total. It began in 2024-01-01 with a primary completion date of 2024-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The main objectives of this study are to evaluate the changes in hemodynamics occurring during the remote ischemic conditioning (RIC) procedure and to compare the hemodynamic responses elicited by passive leg raising before and after the RIC intervention.

Eligibility Criteria

Inclusion Criteria: * aged over 18 years, * admitted to the intensive care unit, * monitored with a transpulmonary thermodilution device with calibrated pulse contour analysis (Pulsion Medical Systems, Munich, Germany), * decision by the physician in charge to perform passive leg raising. Exclusion Criteria: * pregnancy, * advanced malignancy, * peripheral artery disease affecting both arms, * head trauma, * deep vein thrombosis in the lower limbs, * intra-abdominal hypertension, defined as an intra-abdominal pressure greater than 12 mmHg.

Contact & Investigator

Central Contact

Andrius Pranskunas, PhD, prof.

✉ andrius.pranskunas@lsmu.lt

📞 +37037326425

Principal Investigator

Andrius Pranskunas, PhD, prof.

PRINCIPAL INVESTIGATOR

Lithuanian University of Health Sciences

Frequently Asked Questions

Who can join the NCT06536231 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 85 Years, studying Critical Illness. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06536231 currently recruiting?

Yes, NCT06536231 is actively recruiting participants. Contact the research team at andrius.pranskunas@lsmu.lt for enrollment information.

Where is the NCT06536231 trial being conducted?

This trial is being conducted at Kaunas, Lithuania.

Who is sponsoring the NCT06536231 clinical trial?

NCT06536231 is sponsored by Lithuanian University of Health Sciences. The principal investigator is Andrius Pranskunas, PhD, prof. at Lithuanian University of Health Sciences. The trial plans to enroll 50 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology